PHRPhreesia, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−4% a year). The price demands less than its three-year revenue growth of 17% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PHR's price assumes
Phreesia, Inc. trades at 74.7× earnings against 46.9× for the median Health Information Services name, more expensive than its own group.
Trailing P/E · Health Information Services median 46.9 · 1.59× the median: the market pays up for this one
- Price / sales
- 1.32
Price / sales · as of 2026-Q3
- Free cash flow yield
- 10%
Free cash flow yield · Health Information Services median 4.5%
- Growth the price implies
- −4.0%
Growth the price implies · The price pays for −4.0% free cash flow growth a year for a decade; revenue has grown 17% a year over the last three.
Details›
- Price / bookas of 2026-Q3
- 1.80
- EV / EBIToperating margin 2.5%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q3
- 1.42
- Healthcare median P/E503 names
- 27.9
- Health Information Services median P/E24 names
- 46.9
- Free cash flow, trailing twelve months
- $81M
- Market capitalisation62.1 million shares, counted Aug 27, 2026
- $788M
- 3-year revenue growth
- +17%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Health Information Services
Ranks #10 of 18 by RyuScore